Therapeutic Efficacy of an Oncolytic Influenza Virus Carrying an Antibody Against Programmed Cell Death 1 in Hepatocellular Carcinoma

Autor:	Guanglin, Lei, Baofa, Li, Hao, Yang, Fang, Sun, Donghui, Li, Jin, Yan, Yonggang, Wang, Ruisheng, Li, Honghong, Liu, Shaogeng, Zhang, Yufeng, Li, Penghui, Yang
Rok vydání:	2022
Předmět:	Oncolytic Virotherapy Carcinoma Hepatocellular Liver Neoplasms Programmed Cell Death 1 Receptor Antibodies Monoclonal Apoptosis Orthomyxoviridae Disease Models Animal Mice Oncolytic Viruses Cell Line Tumor Genetics Animals Humans Molecular Medicine Molecular Biology
Zdroj:	Human Gene Therapy. 33:309-317
ISSN:	1557-7422 1043-0342
Popis:	Oncolytic virus therapy is a promising novel immunotherapy. In this report, we engineered a novel oncolytic influenza virus (IV) carrying an antihuman programmed cell death 1 (PD-1) monoclonal antibody utilizing reverse genetics. A reassortant chimeric IV, named rFlu-huPD1, was synthesized as follows: the heavy chain of the PD-1 antibody was encoded on the PB1 fragment, and the light chain of the PD-1 antibody was encoded on the polymerase acid protein fragment. rFlu-huPD1 antibodies were produced in infected ovalantoic eggs and could replicate to high titers. Moreover, selective cytotoxicity of rFlu-huPD1 was upregulated in multiple hepatocellular carcinoma (HCC) cell lines compared with a control, as determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Furthermore, the activation of T cells in the spleen of tumor-bearing BALB/c mice treated with rFlu-huPD1 was observed, especially cytotoxic CD8
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db4d661ceb20037f84f31759ae1142e2 https://doi.org/10.1089/hum.2021.167 Zobrazit plný text záznamu